As suggested by recent studies demonstrating the failure of anti-MdmX strategy in tumors expressing hypomorphic p53 mutant,46 our data indicate that cancer treatments centered on MdmX inhibition should be employed only in cases where tumor retains functional p53. Here, MDM4 is linked to cancer.